Similarly, the DESTINY-Breast05 trial is directly comparing the head-to-head efficacy of T-DXd versus T-DM1 in HER2-positive BC patients with residual disease following neoadjuvant therapy (NCT04622319). Here, ERBB2 is linked to breast cancer.